---
title: "T-cell therapeutics for solid tumors: editorial page lacked full text in Frontiers in Immunology"
id: "frontiers-in-immunology-16-editorial-improving-efficacy-and-expanding-the-reach-of-t-cell-therapeutics-for"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-editorial-improving-efficacy-and-expanding-the-reach-of-t-cell-therapeutics-for"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.2038020"
published_at: "2026-11-16T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# T-cell therapeutics for solid tumors: editorial page lacked full text in Frontiers in Immunology
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-editorial-improving-efficacy-and-expanding-the-reach-of-t-cell-therapeutics-for
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.2038020)
- **Published At:** 2026-11-16T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The source link pointed to Frontiers in Immunology but the page content available to this rewrite contained only site navigation and metadata, not the editorial full text. - The document header identified an EDITORIAL and provided the citation line Front. Immunol., 16, but no body text, author list, or abstract were present on the captured page. - Because the source did not include methods, conclusions, or clinical recommendations, no clinical outcomes, trial data, or specific therapeutic approaches can be summarized from it. - Readers seeking content on **T-cell therapeutics** and **solid tumors** must consult the journal site directly for the full editorial; this rewrite therefore focuses on what the captured source did report and lists explicit unanswered questions. - Key editorial elements missing from the source include author names, publication date, stated aims, discussion points, referenced studies, and any translational or regulatory notes. - The absence of substantive content prevents reporting on endpoints, safety signals, manufacturing approaches, antigen targets, or patient cohorts; those details were not available in the source capture. - This note documents the gap between the article title and accessible content, and provides a checklist of items clinicians and researchers should verify when retrieving the full editorial on **Frontiers in Immunology**.
## Clinical Analysis & Structured Key Points
Frontiers | Editorial: Improving efficacy and expanding the reach of T-cell therapeutics for solid tumors: an end-to-end perspective EDITORIAL article Front. Immunol. , 16 November 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.2038020 Published in Frontiers in Immunology Cancer Immunity and Immunotherapy 7 impact factor 11.3 citescore Part of a Research Topic Improving Efficacy and Expanding the Reach of T-Cell Therapeutics for Solid Tumors: An End-to-End Perspective 43k views 14 articles Editor & Reviewers Edited and reviewed by P B Peter Brossart Outline EDITORIAL article Front. Immunol. , 16 November 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.2038020 Editorial: Improving efficacy and expanding the reach of T-cell therapeutics for solid tumors: an end-to-end perspective V R Vikram R. Juneja 1 * G M Gavin M. Bendle 2 * E T Eric Tran 3 * M M Marit M. van Buuren 1 † * 1. BioNTech US, Inc., Cambridge, MA, United States 2. AstraZeneca, Amsterdam, Netherlands 3. Earle A. Chiles Research Institute, a division of Providence Cancer Institute, Portland, OR, United States See more Article metrics View details Editorial on the Research Topic Improving efficacy and expanding the reach of T-cell therapeutics for solid tumors: an end-to-end perspective T-cell therapeutics for solid tumors represent one of the most promising, and most challenging, pursuits in oncology. The field is based on using T cells as a living drug, capable of tumor-specific recognition, in vivo expansion, persistence, and, in some cases, mediating cures ( 1 ). In hematologic malignancies, this concept has already transformed outcomes for some patients ( 2 ). In solid tumors, the path has been harder, but the approval of TIL therapy in melanoma together with the emergence of engineered T-cell approaches in solid tumors, including the first approvals, mark major milestones for the field ( 3 – 5 ). Yet these advances also come as the field faces increasing headwinds from the complexity and cost of autologous ex vivo manufacturing, prompting rapid development of solutions ranging from approaches that simplify ex vivo manufacturing to in vivo engineering ( 6 ). Recent clinical experience exemplifies why the field deserves maintained commitment. In a striking case study, Mair et al. reported a profound response in a pediatric patient with advanced kidney cancer treated with a point-of-care manufactured PRAME-targeted TCR-T product, an outcome that captures what may be uniquely possible with cell therapy in aggressive solid cancers ( 7 ). Cases such as this do not yet define the norm, but they remind us that T-cell therapeutics can mediate responses of a depth and quality that conventional modalities rarely achieve, and they justify continued efforts to make such responses more reproducible and more widely available. That challenge - improving efficacy while expanding access - now defines the next phase of the field. Despite real progress, the most compelling responses remain limited to relatively few targets, indications, and treatment settings, and even within those settings, these therapies are not broadly available ( 8 ). The key challenges can be binned into a few categories: targeting tumor antigens with sufficient specificity and breadth, enabling engineered or expanded T cells to function within hostile tumor microenvironments, and overcoming the cost, complexity, and logistical constraints of manufacturing and delivery. This Research Topic reflects the end-to-end perspective that efficacy and scalability are both critical design goals for T-cell therapeutics. In solid tumors, the problem of tumor recognition is not simply finding a target, but finding one that is selective enough to preserve safety, prevalent enough to be practical clinically, and expressed at sufficient levels to enable durable immune pressure. Hu et al. review the opportunity and limitations of TCR-T therapy for solid tumors, emphasizing its major conceptual advantage: access to intracellular antigens through peptide–HLA recognition to expand targetable space beyond surface antigens. TCRs are inherently cross-reactive, being able to recognize multiple distinct peptide-HLA complexes, and Sharma et al. describe a high-throughput functional screening strategy to profile TCR cross-reactivity against large self-antigen libraries, offering a practical framework for identifying off-target autoreactivity before it reaches the clinic. Monteiro et al. contribute a complementary advance with TRACE, a TCR clonotype-level classifier that can identify tumor-reactive CD8+ T cells from single-cell transcriptional data across datasets and tumor types. Tools of this kind are important for characterizing natural anti-tumor T-cell responses to potentially identify targetable nodes. The collection also highlights the concept that solid-tumor targeting lies not only in finding new targets, but in achieving greater precision in how familiar ones are detected and engaged. Scholler et al. focus on mesothelin, a target of longstanding interest, and show that directing CAR recognition to the juxtamembrane stump may address two challenges of antigen shedding: loss of membrane-proximal target and decoy interference by soluble antigen. Lindenbergh et al. extend this theme by showing that CD70 can be productively targeted in a subset of breast cancers and that enhanced-sensitivity receptor designs can outperform conventional CARs when antigen density is limiting. However, even T cells precisely targeted against tumors must survive and function in a hostile tumor microenvironment. Chronic antigen exposure, inhibitory ligands, suppressive cells, nutrient deprivation, and oxidative stress all serve as barriers to optimal T-cell function in tumors. For that reason, the next generation of T-cell therapeutics will need to be engineered not just for specificity, but also for durability and potency. McPhedran et al. review how reactive oxygen species, methionine metabolism, and GCN2 signaling form an integrated redox-metabolic circuit that shapes T-cell function in solid tumors, emphasizing that metabolic interventions are likely to be highly context dependent. Toumi et al. survey a class of fusion protein-based and switch-receptor strategies designed to convert suppressive microenvironmental signals into productive costimulation or broader tumor remodeling. Wong et al. add a discovery-oriented perspective, highlighting how pooled CRISPR screens can identify pathways that regulate anti-tumor function across the sequential barriers encountered by T cells in solid tumors. Several examples now translate such insights into therapeutic engineering, using targeted knock out of genes identified through such studies to further enhance T-cell potency and persistence (NCT05617755, NCT06598371, NCT05643742). Just as improved recognition and improved fitness are necessary to deepen responses, manufacturing innovation is necessary to broaden reach. Importantly, autologous ex vivo T-cell therapies are currently the most powerful platform for validating targets, testing receptor architectures, understanding resistance, and generating proof-of-concept for the modifications that may ultimately transform outcomes in solid tumors. However, the cost, complexity, and uncertain commercial scalability of autologous ex vivo manufacturing mean that industry efforts are primarily focused on potentially more scalable alternatives like allogeneic and in vivo technologies. For that reason, academic centers and other ambitious translational groups have an important role to play in pressure-testing novel approaches using autologous ex vivo platforms. The papers in this collection demonstrate systematic innovation in manufacturing approaches that can potentially improve scalability and biological performance. Lievense et al. show that a manufacturing process developed for melanoma-derived TILs can be adapted into a tumor-agnostic platform for multiple solid tumor types, an important step toward streamlining the clinical development of TIL therapies across indications. Shih et al. report a rapid clinical-scale manufacturing protocol for KRAS-targeted TCR-T cells that yields products enriched for early-memory and tissue-resident-like features along with enhanced effector function, illustrating how process changes can improve product biology as well as operational feasibility. Ormhøj et al. demonstrate that artificial antigen-presenting scaffolds incorporating Neo2/15 (a cytokine that selectively binds to effector T cells rather than Tregs) can drive expansion of antigen-specific T cells with favorable cytotoxic and functional properties. Successful innovations developed in autologous ex vivo systems should, where possible, be translated into modalities that can better address access and logistics. Park and Cheung discuss ex vivo armed T cells (EATs), which are activated and expanded T cells redirected to the tumor through coating with bispecific antibodies rather than genetic engineering. This is an alternative modality that may combine targeting flexibility with a potentially more adaptable translational path. Bushara et al. review one of the major challenges in allogeneic T-cell therapy - avoiding NK-cell-mediated rejection of HLA-deficient donor cells - and outline immune-evasive strategies that may enable more durable off-the-shelf products. Towards the same goal of reducing cost of goods to the level of biologic therapies, in vivo engineering approaches have garnered increasing attention and investment ( 9 ). The ability to generate or modify therapeutic T cells directly within the patient could reduce manufacturing burden, shorten time to treatment, and expand access beyond highly specialized centers, while also potentially leading to a more optimal T-cell state by eliminating ex vivo handling and culture. The coming years should help clarify whether in vivo engineering can achieve the precision, potency, and safety required for solid tumors. Where should the field go next? First, it should aim for cures or near-curative responses, not settle for modest gains, which will likely require substantial improvements in potency. Autologous ex vivo systems should remain a core platform for innovation in the near-term, especially in academic settings where mechanistic learning can be prioritized over a direct commercial path. Second, it should prioritize broader access through point-of-care manufacturing, allogeneic platforms, and in vivo cell engineering approaches, while maintaining favorable safety profiles. Finally, it should broaden innovation beyond the cell product itself to include lymphodepletion optimization and removal if possible, re-dosing strategies, rational combinations, earlier-line deployment, and a more systematic evaluation of resistance mechanisms. The field of T-cell therapeutics for solid tumors has entered a phase in which proof of concept is no longer enough. The challenge now is to make these therapies work more reliably, more deeply, and for more patients. The studies assembled in this collection demonstrate that doing so will require progress across the full arc of development, from target selection and cell engineering to manufacturing and deployment. Addressing these end-to-end challenges is the path by which the rare exceptional response may become something more common. Statements Author contributions VJ: Writing – original draft, Writing – review & editing. GB: Writing – original draft, Writing – review & editing. ET: Writing – original draft, Writing – review & editing. MB: Writing – original draft, Writing – review & editing. Conflict of interest VJ is employed by BioNTech US, Inc. GB is employed by AstraZeneca. ET was a consultant for AstraZeneca and is a consultant for Pathfinder Oncology. MvB was employed by BioNTech US, Inc. Generative AI statement The author(s) declared that generative AI was used in the creation of this manuscript. Generative AI was used as an editorial tool. Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us. Publisher’s note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. References 1 Rosenberg SA Restifo NP . Adoptive cell transfer as personalized immunotherapy for human cancer . Science . ( 2015 ) 348 : 62–8 . doi: 10.1126/science.aaa4967 Pubmed Abstract CrossRef Google Scholar View reference in article 2 Cappell KM Kochenderfer JN . Long-term outcomes following CAR T cell therapy: What we know so far . Nat Rev Clin Oncol . ( 2023 ) 20 : 359–71 . doi: 10.1038/s41571-023-00754-1 Pubmed Abstract CrossRef Google Scholar View reference in article 3 Chesney J Lewis KD Kluger H Hamid O Whitman E Thomas S et al . Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: Pooled analysis of consecutive cohorts of the C-144-01 study . J Immunother Cancer . ( 2022 ) 10 : e005755 . doi: 10.1136/jitc-2022-005755 Pubmed Abstract CrossRef Google Scholar View reference in article 4 D’Angelo SP Araujo DM Abdul Razak AR Agulnik M Attia S Blay JY et al . Afami-cel (Adaptimmune ADP-A2M4) in synovial sarcoma: Primary efficacy and safety results from the historically controlled, single-arm, phase 2 SPEARHEAD-1 trial . Lancet . ( 2024 ) 403 : 1460–71 . doi: 10.1016/S0140-6736(24)00319-2 CrossRef Google Scholar View reference in article 5 Qi C Liu C Peng Z Zhang Y Wei J Qiu W et al . Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): A randomised, open-label, phase 2 trial . Lancet . ( 2025 ) 405 : 2049–60 . doi: 10.1016/s0140-6736(25)00860-8 Pubmed Abstract CrossRef Google Scholar View reference in article 6 Marchal I . Making cell therapy accessible: Challenges and opportunities . Nat Biotechnol . ( 2025 ) 43 : 482–6 . doi: 10.1038/s41587-025-02625-9 Pubmed Abstract CrossRef Google Scholar View reference in article 7 Mair Rossi C Westhoff JH Grünewald TGP Schenk JP Tuch A et al . PRAME-targeted TCR-T therapy in a pediatric patient with advanced kidney cancer . N Engl J Med . ( 2026 ) 395 ( 7 ): 721–4 . doi: 10.1056/NEJMc2605154 CrossRef Google Scholar View reference in article 8 Reinhorn D Tak WS Haanen JBAG D'Angelo SP Fashoyin-Aje LA . Autologous T-cell therapies in solid tumor malignancies: Current landscape and future opportunities . Am Soc Clin Oncol Educ Book . ( 2025 ) 45 : e473440 . doi: 10.1200/edbk-25-473440 Pubmed Abstract CrossRef Google Scholar View reference in article 9 Aalipour A Barreiro A Garmilla A Birnbaum ME . In vivo CAR T-cell engineering: Design principles and open questions . Trends Cancer . ( 2026 ) 12 : 434–46 . doi: 10.1016/j.trecan.2026.01.007 Pubmed Abstract CrossRef Google Scholar View reference in article Summary Keywords adoptive cell therapy (ACT) , CAR-T , cell therapy manufacturing , T-cell modulation , T-cell therapies , TCR-T , TIL therapy , tumor microenvironment (TME) Citation Juneja VR, Bendle GM, Tran E and van Buuren MM (2026) Editorial: Improving efficacy and expanding the reach of T-cell therapeutics for solid tumors: an end-to-end perspective . Front. Immunol. 17:2038020. doi: 10.3389/fimmu.2026.2038020 Received 22 October 2026 Revised 22 October 2026 Accepted 23 October 2026 Published 16 November 2026 Volume 17 - 2026 Edited and reviewed by Peter Brossart , University of Bonn, Germany Updates Check for updates Copyright © 2026 Juneja, Bendle, Tran and van Buuren. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. * Correspondence: Vikram R. Juneja, vikram.juneja@biontech.us ; Gavin M. Bendle, gavin.bendle@astrazeneca.com ; Eric Tran, eric.tran@providence.org ; Marit M. van Buuren, mvanbuuren@thirdrockventures.com †Present address: Marit M. van Buuren, Third Rock Ventures, Boston, MA, United States Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. Article metrics View details Download PDF Download other formats ReadCube epub XML Cite article Share article Our quality Expert judgment makes science stronger Behind every published article stand expert reviewers safeguarding science. Discover our rigorous approach to peer review. Learn about peer review Outline Cite article Copy to clipboard Copy citation Export citation file BibTex EndNote Reference Manager Simple Text file Share article Facebook X LinkedIn Email WeChat Share on WeChat Scan with WeChat to share this article Article metrics
## Related Clinical Research

- [Cell Therapy's Role in Humoral Alloimmunity Post-Transplantation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-cell-therapy-and-humoral-alloimmunity-post-transplantation-a-review-of.md)
- [Fecal Microbiome and Metabolome During Immunotherapy-Based Total Neoadjuvant Therapy in Rectal Can](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-commentary-fecal-microbiome-and-metabolome-dynamics-during-immunotherapy-based.md)
- [What an 1834 mother’s measles letter reveals about MAHA and public health trust](https://medichelpline.com/clinical-feed/stat-news-0-opinion-what-a-mother-s-1834-letter-about-measles-tells-us-about-maha.md)
- [Marine-derived compound shows activity against Naegleria fowleri in lab tests](https://medichelpline.com/clinical-feed/stat-news-1-a-possible-treatment-for-brain-eating-amoebas-found-in-the-sea.md)
- [Lassa fever CFR rise in Nigeria linked to retroactive deaths, not clinical decline](https://medichelpline.com/clinical-feed/medrxiv-1-interpreting-changes-in-reported-case-fatality-in-endemic-zoonoses-an.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.